Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity ofcis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline

Summary

Four drugs known to interact with topoisomerase II were assessed for their ability to enhance the cytotoxicity ofcis-diamminedichloroplatinum(II) (CDDP) in Chinese hamster ovary (CHO) cell lines sensitive and resistant to VM-26. The combination treatments were analyzed by isobologram methodology. On 24 h exposure, there was no significant difference in the cytotoxicity of novobiocin or ciprofloxacin toward either cell line. The resistant cells were approximately 9-fold more resistant to 4′-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and approximately 170-fold more resistant to etoposide after a 24-h exposure. The combination of novobiocin and cisplatin produced greater than additive cell kill over the entire dose range of cisplatin tested in both cell lines.m-AMSA and CDDP produced cell kill that fell within the envelope of additivity. Etoposide and CDDP resulted in cytotoxicity that was slightly greater than additive at low CDDP concentrations and additive at the highest concentration of CDDP tested in the parental cell line and was slightly greater than additive in the resistant cell line. Ciprofloxacin and CDDP, like novobiocin, resulted in greater than additive cell kill in both cell lines. The enhancement of CDDP cytotoxicity by novobiocin that was seen in exponentially growing cells was lost in stationary-phase cultures. In these studies, novobiocin and, to a lesser degree, ciprofloxacin produced greater than additive cell kill in combination with CDDP in parental and epipodophyllotoxin-resistant CHO cells.

This is a preview of subscription content, log in to check access.

Abbreviations

CDDP:

cis-diamminedichloroplatinum(II)

m-AMSA:

4′-(9-acridinylamino)methanesulfon-m-anisidide

IC90 :

drug concentration require for the inhibition of colony formation by 90%

References

  1. 1.

    Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. Clin Exp Immunol 28: 1

  2. 2.

    Constantinou A, Henning-Chubb C, Huberman E (1989) Novobiocin and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity. Cancer Res 49: 1110

  3. 3.

    Deen DF, Williams MW (1987) Isobologram analysis of X-ray-BCNU interactions in vitro. Radiat Res 79: 483

  4. 4.

    Drlica K, Francod RJ (1988) Inhibitors of DNA topoisomerases. Biochemistry 27: 2253

  5. 5.

    Edenberg H (1980) Novobiocin inhibition of simian virus 40 replication. Nature 286: 529

  6. 6.

    Eder JP, Teicher BA, Holden SA, Cathcart KNS, Schnipper LE (1987) Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model. J Clin Invest 79: 1524

  7. 7.

    Eder JP, Teicher BA, Holden SA, Cathcart KNS, Schnipper LE, Frei E III (1989) Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents. Cancer Res 49: 595

  8. 8.

    Fraval HNA, Roberts JJ (1979) Gl phase Chinese hamster V79-379A cells are inherently more sensitive to platinum bound to their DNA than mid-S phase or asynchronously treated cells. Biochem Pharmacol 28: 1575

  9. 9.

    Gellert M, O’Dea MH, Itah T, Tomizawa J (1976) Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase. Proc Natl Acad Sci USA 73: 4474

  10. 10.

    Glisson B, Gupta R, Hodges P, Ross W (1986) Cross resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res 46: 1939

  11. 11.

    Glisson B, Gupta R, Smallwood-Kenho S, Ross W (1986) Characterization of acquired epipodophyllotoxin-resistance in a Chinese hamster ovary cell line: loss of drug stimulated DNA cleavage activity. Cancer Res 46: 1934

  12. 12.

    Gupta RS (1983) Genetic, biochemical and cross resistant studies with mutants of Chinese hamster ovary cells resistant to the anti-cancer drugs VM-26 and VP-16-213. Cancer Res 43: 1568

  13. 13.

    Holm CT, Gato T, Wang JC, Botstein D (1985) DNA topoisomerase II is required at the time of mitosis in yeast. Cell 41: 553

  14. 14.

    Marracino RL, Wohl AF, Keng PC, Lord EM, Bambara RA (1987) Cell cycle dependent activities of DNA polymerase alpha and delta in Chinese hamster ovary cells. Biochemistry 26: 7864

  15. 15.

    Mattern MR, Scudiero DA (1981) Characterization of the inhibition of replicative and repair type DNA synthesis by novobiocin and nalidixic acid. Biochim Biophys Acta 653: 248

  16. 16.

    Meyn RE, Jenkins SF, Tompson LH (1982) Defective removal of DNA crosslink in a repair-deficient mutant of Chinese hamster cells. Cancer Res 42: 3106

  17. 17.

    Prem veer Reddy G, Pardee A (1983) Inhibitor evidence for allosteric interaction in the replicase complex. Nature 304: 86

  18. 18.

    Roberts JJ, Fraval HNA (1978) The interaction of antitumor platinum compounds with cellular DNA in cultured cells and animal tissues: relationship to DNA cellular repair processes. Biochimie 60: 869

  19. 19.

    Ross WE (1985) DNA topoisomerases as targets for cancer therapy. Biochem Pharmacol 34 (24): 4191

  20. 20.

    Ryaji M, Worcel A (1984) Chromatin assembly inXenopus oocytes: in vivo studies. Cell 37: 21

  21. 21.

    Sedgwick B, Lindahl T (1982) A common mechanism for the repair of 06 methylguanine and 06 ethylguanine in LDNA. J Mol Biol 154: 169

  22. 22.

    Steel GG, Peckham MJ (1979) Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 5: 85

  23. 23.

    Sullivan DM, Latham MD, Ross WE (1987) Proliferation dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 47: 3973

  24. 24.

    Sullivan D, Latham MD, Rowe TC, Ross WR (1989) Purification and characterization of a topoisomerase II mutant from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28: 5680

  25. 25.

    Tan KB, Mattern MR, Boyce RA, Schein PS (1987) Elevated topoisomerase II activity in nitrogen mustard-resistant cell lines. Proc Natl Acad Sci USA 84: 7668

  26. 26.

    Teicher BA, Holden SA, Cucchi CA, Cathcart KNS, Korbut TT, Flatow JL, Frei E III (1988) Combination ofN, N′, N″-triethylenethiophosphoramide and cyclophosphamide in vitro and in vivo. Cancer Res 48: 94

  27. 27.

    Wang JC (1987) Recent studies of DNA topoisomerases. Biochim Biophys Acta 909: 1

  28. 28.

    Zwelling LA, Michaels S, Schwartz H, Dobson P, Kohn KW (1981) DNA crosslinking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cisplatin andl-phenylalanine mustard. Cancer Res 41: 640

Download references

Author information

Correspondence to Joseph P. Eder.

Additional information

This work was supported by NCI grant PO1 CA38493 and by the Mathers Foundation

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Eder, J.P., Teicher, B.A., Holden, S.A. et al. Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity ofcis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline. Cancer Chemother Pharmacol 26, 423–428 (1990). https://doi.org/10.1007/BF02994093

Download citation

Keywords

  • Etoposide
  • CDDP
  • Chinese Hamster Ovary Cell
  • Parental Cell Line
  • Resistant Cell Line